LS132.1D9 [1D9]細胞
生長狀態： 懸浮生長
ATCC Number： HB-12549?
是否是腫瘤細胞： 0
物種來源： 小鼠
運輸方式： 凍存運輸
數量： 大量
**類型： IgG2a kappa
Designations: LS132.1D9 [1D9]
LS132.1D9 [1D9]細胞Depositors: LeukoSite, Inc.
Isotype: IgG2a kappa
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma)
Morphology:
Source: Cell Type: hybridoma:
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material.LS132.1D9 [1D9]細胞 Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2).
Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose and supplemented with 25 mM HEPES, 20 pg/ml mouse recombinant Interleukin-6 (IL-6) and 20% fetal bovine serum
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 X 10(6) cells/ml.
Interval: LS132.1D9 [1D9]細胞Maintain cultures at a cell concentration between 1 X 10(5) and 1 X 10(6) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 71858: LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,312,689 dated Nov 6 2001
71859: LaRosa GJ, et al. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,352,832 dated Mar 5 2002
71860: LaRosa GJ. Method of inhibiting leukocyte trafficking by anti-CCR2 amino-terminal domain antibodies. US Patent 6,395,497 dated May 28 2002
71861: LaRosa GJ. Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies. US Patent 6,406,865 dated Jun 18 2002
71862: LaRosa GJ. Anti-CCR2 antibodies. US Patent 6,406,694 dated Jun 18 2002
71863: LaRosa GJ. Method of inhibiting cell function associated with CCR2 by anti-CCR2 amino-terminal domain antibodies. US Patent 6,448,021 dated Sep 10 2002
71864: LaRosa GJ. LS132.1D9 [1D9]細胞Anti-CCR2 antibodies and methods of use therefor. US Patent 6,451,522 dated Sep 17 2002
71865: . Anti-CCR2 antibodies and methods of use therefor. US Patent 6,458,353 dated Oct 1 2002
71866: LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,491,915 dated Dec 10 2002
